Roles of<scp>ST</scp>2,<scp>IL</scp>‐33 and<scp>BNP</scp>in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention

Wang, Yanpeng; Wang, Jianhua; Wang, Xiaolong; Liu, Junyi; Jiang, Fang-Yun; Huang, Xiaoli; Hang, Junjie; Qin, Wei; Ma, Shujuan; Zhang, Jie; Yuan, Meng; Li, Jingbo; Lu, Zhigang; Wang, Meng

doi:10.1111/jcmm.13183

Cited by 33 publications

(34 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In acute MI cases treated with PCI, BNP was shown to predict one-year major adverse cardiac events (203). In summary, it is possible to say that high NP levels at admission or in-hospital denote poor short-and long-term prognosis in STE ACS cases treated with either thrombolytics or PCI.…”

Section: Bnp In the Assessment Of Risk And Prognosis In St-segment Elmentioning

confidence: 93%

“…In acute MI cases treated with PCI, it was reported that a BNP value above 285.73 pg/mL predicted one-year major adverse cardiac events with 96% sensitivity and 77% specificity (203). Another study reported that the best threshold NT-proBNP value for predicting in-hospital mortality in STEMI cases treated with primary PCI was 2300 pg/mL (201).…”

Section: Is There a Cut-off Value That Can Be Helpful In Clinical Use?mentioning

confidence: 99%

See 1 more Smart Citation

Natriuretic Peptides in Clinical Practice

Çavuşoğlu

Alper²,

Altay³

et al. 2019

Anatol J Cardiol

View full text Add to dashboard Cite

Natriuretic peptides (NP) are commonly used diagnostic biomarkers in heart failure (HF). While the American HF guideline strongly recommends NPs as class I indication with the level of evidence A in the diagnosis of both acute and chronic HF (1), the European HF guideline recommends them as class I indicationwith the level of evidence A for acute HF and as class IIa indication with the level of evidence C for chronic HF (2). Similarly, NPs have been proven to be strong biomarkers for prognosis and risk assessment in HF. The American HF guideline recommends NPs as class I indication with the level of evidence A in the assessment of prognosis of both acute and chronic HF (1). Moreover, the American HF guideline recommends NP monitorization as class IIa indication with the level of evidence B for achieving optimal treatment target in chronic HF (1). However, it Natriuretic peptides have long been introduced into clinical practice. These biomarkers have certainly been shown to provide useful information in the diagnosis, prognosis and risk stratification in heart failure and also may have a role in the guidance of heart failure therapy. Although, there are some limitations in using of these markers such as lack of specificity, aging, renal dysfunction or obesity, among the huge number of candidates for heart failure biomarkers, only natriuretic peptides are currently widely used in daily clinical practice in heart failure. Recent heart failure guidelines recognize natriuretic peptides as an essential tool in the new diagnostic and therapeutic algorithms. Furthermore, natriuretic peptides are not only used in the diagnosis or prognosis of heart failure, but also these biomarkers are referred to have some potential role in primary prevention, cardio-oncology, advanced heart failure, assessment of response to cardiac resynchronization therapy, pulmonary arterial hypertension, acute coronary syndromes, atrial fibrillation and valvular heart disease. In this article, natriuretic peptides have been reviewed for their updated information and new recommendations in heart failure and also potential role of these biomarkers in the management of various clinical conditions have been addressed in the form of expert opinion based on the available data in the literature.

show abstract

Section: Bnp In the Assessment Of Risk And Prognosis In St-segment Elmentioning

confidence: 93%

Section: Is There a Cut-off Value That Can Be Helpful In Clinical Use?mentioning

confidence: 99%

Natriuretic Peptides in Clinical Practice

Çavuşoğlu

Alper²,

Altay³

et al. 2019

Anatol J Cardiol

View full text Add to dashboard Cite

show abstract

“…Elevated ST2 concentration is a predictor of major adverse cardiac events in ACS patients [115]. e serum ST2 level positively correlates with IL-33 and BNP levels, and all of these biomarkers are independent predictors of major adverse cardiac events in AMI patients undergoing PCI [116]. e 2017 ACCF/AHA guidelines for the Management of Heart Failure have specified ST2 receptors and galectin-3 as prognostic biomarkers for the prediction of hospitalization and death and to provide additional prognostic value in patients with HF [117].…”

Section: Suppression Of Tumorigenicity 2 (St2)mentioning

confidence: 99%

The Biomarkers for Acute Myocardial Infarction and Heart Failure

Wang

Zhang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

The use of a large number of cardiovascular biomarkers, meant to complement the use of the electrocardiogram, echocardiography cardiac imaging, and clinical symptom assessment, has become a routine in clinical diagnosis, differential diagnosis, risk stratification, and prognosis and guides the management of patients with suspected cardiovascular diseases. There is a broad consensus that cardiac troponin and natriuretic peptides are the preferred biomarkers in clinical practice for the diagnosis of the acute coronary syndrome and heart failure, respectively, while the roles and possible clinical applications of several other potential biomarkers are still under study. This review mainly focuses on the recent studies of the roles and clinical applications of troponin and natriuretic peptides, which seem to be the best-validated markers in distinguishing and predicting the future cardiac events of patients with suspected cardiovascular diseases. Additionally, the review briefly discusses some of the large number of potential markers that may play a more prominent role in the future.

show abstract

“…levels are elevated early in NSTE-ACS and predict 1-year mortality [10]. Wang YP's research showed that serum levels of ST2, IL-33 and BNP were positively correlate with MACEs in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) [28]. However, there was no study to investigate the long-term value of ST2 in the prediction of MACEs or all cause death in patients with CAD in a large population.…”

Section: Prognosis Value Of St2 On Cardiovascular Diseasementioning

confidence: 99%

Prognostic value of ST2 for MACEs and all-cause mortality in patients with coronary artery disease during a long-term follow up

Duan

Cai

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Suppression of tumorigenesis-2 is implicated in the myocardial overload and it was long been recognized as an inflammation marker related to heart failure and acute coronary syndromes, but the data on prognostic value of suppression of tumorigenesis-2 on patients with coronary artery disease remains limited. The study ought to investigate the prognostic value of suppression of tumorigenesis-2 in patients with established coronary artery disease.Methods: In this prospective cohort study, a total of 3641 consecutive patients were included. The primary end point was major adverse cardiovascular events. Kaplan-Meier survival estimates indicated that the patients with higher levels of ST2 (ST2> 19 ng/ml) had a significantly increased risk of MACEs (log-rank p＜0.001) and all-cause death (log-rank p＜0.001). The secondary end point was all-cause death. The association between suppression of tumorigenesis-2 and outcomes was investigated using multivariable COX regression.Results: During a median follow up of 6.4 years, there were 775 patients had the occurrence of major adverse cardiovascular events and 275 patients died. Kaplan-Meier survival estimates indicated that the patients with higher levels of ST2 (ST2> 19 ng/ml) had a significantly increased risk of MACEs (log-rank p＜0.001) and all-cause death (log-rank p＜0.001). Multiple COX regression models showed that higher level of suppression of tumorigenesis-2 was an independent predictor in developing major adverse cardiovascular events (HR=1.36, 95% CI 1.17-1.56, p＜0.001) and all-cause death (HR=2.01, 95%CI 1.56-2.59, p＜0.001). The addition of suppression of tumorigenesis-2 to established risk factors significantly improved risk prediction of the composite outcome of major adverse cardiovascular events and all-cause death (c-statistic, net reclassification index, and integrated discrimination improvement, all p＜0.05).Conclusions: Higher level of suppression of tumorigenesis-2 is significantly associated with long-term all-cause death and major adverse cardiovascular events. Suppression of tumorigenesis-2 may provide incremental prognostic value beyond traditional risk factors.

show abstract

Roles ofST2,IL‐33 andBNPin predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention

Cited by 33 publications

References 34 publications

Natriuretic Peptides in Clinical Practice

Natriuretic Peptides in Clinical Practice

The Biomarkers for Acute Myocardial Infarction and Heart Failure

Prognostic value of ST2 for MACEs and all-cause mortality in patients with coronary artery disease during a long-term follow up

Contact Info

Product

Resources

About